Insider Selling: Thomas Schall Sold 200,000 Shares of ChemoCentryx, Inc. (CCXI); National Presto Industries (NPK) Sentiment Is 1.03

May 18, 2018 - By Stephen Andrade

ChemoCentryx, Inc. (NASDAQ:CCXI) Logo

National Presto Industries Inc (NPK) investors sentiment decreased to 1.03 in 2017 Q4. It’s down -0.50, from 1.53 in 2017Q3. The ratio is negative, as 60 hedge funds started new or increased stock positions, while 58 sold and trimmed equity positions in National Presto Industries Inc. The hedge funds in our database reported: 4.02 million shares, up from 3.69 million shares in 2017Q3. Also, the number of hedge funds holding National Presto Industries Inc in top ten stock positions was flat from 1 to 1 for the same number . Sold All: 13 Reduced: 45 Increased: 37 New Position: 23.

Thomas Schall, an insider of Chemocentryx Inc, currently President and CEO recently disclosed a sizable trade with the U.S. Security & Exchange Commission. As reported in the report, Thomas Schall purchased 200,000 shares of the Pinksheet-listed Chemocentryx Inc, priced at $11.8 per share. $2,355,862 U.S. Dollars was the trade’s value. The SEC filing’s date was May 17, 2018. Thomas is trying to silently decrease his company’s share, same as he did in the last month. He sold another 50,000 shares worth $550,858 USD. Being a significant trade, it will most likely not go ignored. Thomas Schall now possess 4.45% of Chemocentryx Inc’s market cap with ownership of 2.18 million shares. 

More notable recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: Seekingalpha.com which released: “ChemoCentryx: Discounted, Underfollowed, And Misunderstood Biotech” on May 07, 2018, also Globenewswire.com with their article: “ChemoCentryx Reports First Quarter 2018 Financial Results and Recent Highlights” published on May 09, 2018, Seekingalpha.com published: “ChemoCentryx’s (CCXI) CEO Dr. Thomas Schall on Q1 2018 Results – Earnings Call Transcript” on May 10, 2018. More interesting news about ChemoCentryx, Inc. (NASDAQ:CCXI) were released by: Benzinga.com and their article: “41 Biggest Movers From Yesterday” published on May 17, 2018 as well as Benzinga.com‘s news article titled: “Benzinga’s Top Upgrades, Downgrades For May 16, 2018” with publication date: May 16, 2018.

Since May 1, 2018, it had 0 insider purchases, and 4 insider sales for $1.87 million activity. The insider Cappel Markus J. sold 50,000 shares worth $550,912. Another trade for 50,000 shares valued at $550,858 was made by Schall Thomas J. on Tuesday, May 1. KANAYA SUSAN M sold $752,925 worth of stock or 65,328 shares.

The stock decreased 0.24% or $0.03 during the last trading session, reaching $12.47. About 455,911 shares traded or 50.09% up from the average. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 81.17% since May 18, 2017 and is uptrending. It has outperformed by 69.62% the S&P500.

Among 6 analysts covering ChemoCentryx (NASDAQ:CCXI), 4 have Buy rating, 1 Sell and 1 Hold. Therefore 67% are positive. ChemoCentryx has $20 highest and $1300 lowest target. $16.50’s average target is 32.32% above currents $12.47 stock price. ChemoCentryx had 8 analyst reports since September 3, 2015 according to SRatingsIntel. JMP Securities maintained the shares of CCXI in report on Thursday, August 10 with “Buy” rating. The firm earned “Sell” rating on Thursday, September 3 by Zacks. JP Morgan maintained it with “Overweight” rating and $16 target in Tuesday, March 13 report. The firm has “Hold” rating by Cowen & Co given on Tuesday, August 8. The company was downgraded on Monday, September 21 by Zacks. The stock of ChemoCentryx, Inc. (NASDAQ:CCXI) has “Mkt Outperform” rating given on Tuesday, February 21 by JMP Securities.

Analysts await ChemoCentryx, Inc. (NASDAQ:CCXI) to report earnings on August, 14. They expect $-0.25 earnings per share, down 31.58% or $0.06 from last year’s $-0.19 per share. After $-0.19 actual earnings per share reported by ChemoCentryx, Inc. for the previous quarter, Wall Street now forecasts 31.58% negative EPS growth.

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company has market cap of $612.90 million. The Company’s lead drug candidate is Avacopan , an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor (C5Ar), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). It has a 34.64 P/E ratio. The firm also engages in developing CCX140, an inhibitor of the chemokine receptor known as CCR2 for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease; Vercirnon for the treatment of patients with moderate-to-severe Crohn's diseases; CCX872, a selective inhibitor of the human CCR2 that has completed Phase I clinical trial for the treatment of pancreatic cancer; CCX507, which has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and Th17 cells for the treatment of psoriasis, rheumatoid arthritis, asthma, and multiple sclerosis.

Investors sentiment increased to 1.3 in Q4 2017. Its up 0.16, from 1.14 in 2017Q3. It is positive, as 6 investors sold ChemoCentryx, Inc. shares while 21 reduced holdings. 7 funds opened positions while 28 raised stakes. 23.51 million shares or 1.03% less from 23.75 million shares in 2017Q3 were reported. 945,074 are held by Nantahala Cap Mgmt Llc. Citigroup owns 1,223 shares for 0% of their portfolio. Bridgeway Capital Mngmt Inc holds 52,396 shares or 0% of its portfolio. Credit Suisse Ag has 11,325 shares for 0% of their portfolio. Pub Employees Retirement Sys Of Ohio holds 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI) for 69,613 shares. Moreover, Renaissance Technologies Ltd Liability has 0.01% invested in ChemoCentryx, Inc. (NASDAQ:CCXI). Invesco invested in 77,660 shares or 0% of the stock. Bb&T Securities Ltd Liability reported 83,500 shares. Los Angeles Capital Management Equity Rech has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Morgan Stanley stated it has 150,072 shares or 0% of all its holdings. Manufacturers Life Insurance The owns 8,450 shares for 0% of their portfolio. Legal & General Gru Public Llc stated it has 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Arrowstreet Cap Ltd Partnership invested in 26,016 shares. Barclays Public Ltd Company stated it has 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Spark Invest Mgmt Limited Liability Corporation holds 0.05% in ChemoCentryx, Inc. (NASDAQ:CCXI) or 145,100 shares.

Since January 1, 0001, it had 3 buys, and 0 selling transactions for $50,205 activity.

National Presto Industries, Inc. provides housewares and small appliances, and defense products primarily in North America. The company has market cap of $755.26 million. The firm operates through two divisions, Housewares/Small Appliance and Defense. It has a 14.29 P/E ratio. The Housewares/Small Appliance segment designs, markets, and distributes housewares and small electrical appliances, including pressure cookers and canners; heat control single thermostatic control line of skillets, griddles, woks, and multi-purpose cookers under the Presto Control Master brand; deep fryers; waffle makers; pizza ovens; slicer/shredders; electric heaters; hot air, oil, and microwave corn poppers; dehydrators; rice cookers; microwave bacon cookers; coffeemakers and coffeemaker accessories; electric tea kettles; electric knife sharpeners; kitchen gadgets; and timers.

The stock increased 1.12% or $1.2 during the last trading session, reaching $108.25. About 50,971 shares traded. National Presto Industries, Inc. (NPK) has declined 0.02% since May 18, 2017 and is downtrending. It has underperformed by 11.57% the S&P500.

National Presto Industries, Inc. (NYSE:NPK) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts